Anoro Ellipta is an inhalation powder containing a combination of umeclidinium and vilanterol. Umeclidinium is an anticholinergic. Vilanterol is a bronchodilator. These medications work by relaxing muscles in the airways to improve breathing. Anoro Ellipta is used to prevent airflow obstruction or bronchospasm in people with COPD (chronic obstructive pulmonary disease). Anoro Ellipta may also be used for purposes not listed in this medication guide.
Anoro Ellipta is an inhalation powder that contains a combination of two components. Anoro Ellipta contains umeclidinium, an anticholinergic. Anoro Ellipta also contains Vilanterol which is a bronchodilator. These medications are work by relaxing muscles in the airways to improve breathing. Anoro Ellipta is used by medical practitioners to prevent airflow obstruction or bronchospasm in people who have COPD and other chronic lung issues.
Anoro Ellipta is a medicine used in the treatment of bronchospasm, or airway obstruction, in patients with chronic obstructive pulmonary disease (COPD). Anoro Ellipta has two active ingredients, umeclidinium and vilanterol, both of which work by different means. Umeclidinium is an anti-cholinergic drug, preventing the actions of acetylcholine (a neurotransmitter which promotes muscle tension), whereas vilanterol is a bronchodilator - meaning it expands the volume of the bronchi of the lungs.
Anoro Ellipta is administered via the inhalation route. The typical dose for patients with COPD is one dose per day. Patients are advised not to exceed this dose. Common side effects with Anoro Ellipta include stuff nose, sinus pain, chest pain, muscle spasms, and pain in the neck.